TIAN-SHAN1 Study: DZD6008 for Advanced NSCLC with EGFR Mutations
This study is testing a new oral medicine called DZD6008 for people with advanced non-small cell lung cancer (NSCLC) that has specific changes in the EGFR gene. It will also compare DZD6008 to another medicine called Sunvozertinib. The main goals are to see how safe DZD6008 is and how well it works to shrink tumors. To join, you must be at least 18 years old, have advanced NSCLC that can't be cured by other treatments, and have a confirmed EGFR gene mutation. The study is currently unclear about its recruitment status and plans to enroll about 140 people.
- Study design
- This study is an interventional study with a planned enrollment of 140 participants. It has two parts: Part A (dose escalation) and Part B (dose expansion).
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and anti-tumor activity will be measured through the study completion, which is an average of around 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
At a glance
Conditions
Where it's being run
5 sites across 3 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Part A: To assess safety and tolerability21 days after the first multiple dose
Number of participants with Dose-limiting Toxicities (DLTs)
- Part A: To assess safety and tolerabilityThrough the study completion, an average of around 1 year
Number of participants with Adverse events (AEs)/Serious adverse events (SAEs)
- Part B: To assess anti-tumor activityThrough the study completion, an average of around 1 year
Objective Response Rate (ORR) assessed by investigators per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1